美股异动 | 减肥药概念股走强 硕迪生物(GPCR.US)涨超5%

Group 1 - The core viewpoint of the article highlights the strong performance of U.S. weight loss drug stocks, with notable gains in companies such as Gelesis (GPCR.US), Novo Nordisk (NVO.US), Roche (RHHBY.US), and Eli Lilly (LLY.US) [1] - Gelesis reported positive top-line results for its oral small molecule GLP-1 receptor agonist, aleniglipron, in the ACCESS clinical trial [1]